SEASTAR: A Phase 1b/2, Open-label, Parallel Arm Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor
Latest Information Update: 18 Jan 2024
At a glance
- Drugs Lucitanib (Primary) ; Rucaparib (Primary) ; Sacituzumab govitecan (Primary)
- Indications Advanced breast cancer; Carcinoma; Endometrial cancer; Ovarian cancer; Solid tumours; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms SEASTAR
- Sponsors Clovis Oncology [CEASED]; pharmaand GmbH
Most Recent Events
- 13 Sep 2023 Number of treatment arms has been changed to 3, primary endpoint has been amended and trial focus has now shifted to Tu only.
- 26 Jul 2022 Status changed from active, no longer recruiting to discontinued. Reason the study was stopped: Due to a change in development priorities, no further clinical development of the lucitanibplus rucaparib or lucitanib plus sacituzumab govitecan combinations is planned at this time.
- 08 Jun 2021 Results (as of 1 Feb 2021; n= 16) presented at the 57th Annual Meeting of the American Society of Clinical Oncology.